Investigational New Drugs
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action
Investigational New Drugs - Tập 15 - Trang 49-59 - 1997
Angiogenesis is a biologic process whereby endothelial cells divide and migrate to form new blood vessels. This process is required in physiological conditions, but is also a necessary requirement for solid tumors to grow and metastasize. Over the last several years, the growth factors that have both a positive and negative influence on tumor angiogenesis have been delineated. Interfering with tum......
New microtubular agents in pediatric oncology
Investigational New Drugs - Tập 14 - Trang 49-54 - 1996
The taxanes are a new group of anticancer agents with a novel mechanism of action. They promote microtubule assembly and stabilize the microtubules. Paclitaxel (Taxol), the first agent in this group in clinical trials was isolated from the Pacific yew, Taxus brevifolia in 1971. Both in preclinical and clinical studies, paclitaxel and its semisynthetic analog docetaxel exhibit significant antitumor......
Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone
Investigational New Drugs - Tập 1 - Trang 341-347 - 1983
A prospective Phase II study to evaluate the effects of mitoxantrone on left ventricular ejection fraction (LVEF) has been carried out in patients treated with 12 mg/m2 every three weeks. Gated radionuclide cardiac blood pool imaging with assessment of LVEF and wall motion prior to and during graded exercise was performed before the first and every other mitoxantrone course. Ten patients had eithe......
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells
Investigational New Drugs - Tập 41 - Trang 541-550 - 2023
TP53 (p53) and MYC are amongst the most frequently altered genes in cancer. Both are thus attractive targets for new anticancer therapies. Historically, however, both genes have proved challenging to target and currently there is no approved therapy against either. The aim of this study was to investigate the effect of the mutant p53 reactivating drug, COTI-2 on MYC. Total MYC, pSer62 MYC and pThr......
Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer
Investigational New Drugs - Tập 20 - Trang 183-194 - 2002
Prostate cancer is the most frequentlydiagnosed malignancy and the second mostcommon cause of cancer-related death in menin the United States. Unfortunately, atthe current time, no curative treatmentsare available for metastatic prostatecancer. As is the case for most solidtumors, the recruitment of blood vessels(angiogenesis) is key for the progressionand metastasis of prostate cancer. Inhibition......
Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer
Investigational New Drugs - Tập 8 - Trang 283-287 - 1990
We have carried out a phase II study of intravenous menogaril given every four weeks in a group of patients with breast cancer who had received no prior chemotherapy for metastatic disease. Myelosuppression, nausea and vomiting and local reactions were seen frequently. Six partial responses (median duration 154 days) were seen in 24 eligible patients. We conclude menogaril is active in breast canc......
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model
Investigational New Drugs - Tập 34 - Trang 693-700 - 2016
Purpose A novel doxorubicin (DOX) analog, 13-deoxy, 5-iminodoxorubicin (DIDOX), was synthesized to prevent quinone redox cycling and alcohol metabolite formation, two prevailing hypotheses of anthracycline cardiotoxicity. The chronic cardiotoxicity of DOX and DIDOX was compared. Since a recent hypothesis posits that DOX-induced chronic cardiotoxicity may be mediated by inh......
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells
Investigational New Drugs - Tập 38 - Trang 1292-1302 - 2020
Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (PCa) that has entered phase III clinical trials. In the present study, we intended to elucidate the antitumor efficacy of proxalutamide through the metabolomic profiling of PCa cells. Two AR-positive PCa cell lines and two AR-negative PCa cell lines were investigated. Cel......
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Investigational New Drugs - Tập 41 - Trang 402-410 - 2023
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. This open-label, parallel-group study investigated the effect of chronic hepatic impairment on the pharmacokinetics (PK) of brigatinib to inform dosing recommendations for these patients. Participants with hepatic impairment classified according to Child-Pugh categorie......
A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
Investigational New Drugs - Tập 40 - Trang 308-313 - 2021
Background. Anlotinib hydrochloride is an oral small molecule inhibitor of multiple tyrosine kinases, and it has been approved as a third-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) in China. This dose-exploration study was designed to investigate the feasibility of anlotinib in combination with other chemotherapy regimens in patients with nonsquamous NSCLC. Methods.......
Tổng số: 2,524
- 1
- 2
- 3
- 4
- 5
- 6
- 10